Azitra (NYSEAMERICAN:AZTR – Get Free Report) is expected to release its results before the market opens on Monday, February 23rd. Analysts expect Azitra to post earnings of ($0.37) per share for the quarter.
Azitra Stock Down 3.4%
Shares of AZTR stock opened at $0.20 on Monday. Azitra has a 1-year low of $0.19 and a 1-year high of $2.97. The stock has a 50 day simple moving average of $0.28 and a 200-day simple moving average of $0.56.
About Azitra
Azitra Inc is a clinical-stage biopharmaceutical company focused on developing live bacterial therapies for dermatological conditions. Headquartered in Cambridge, Massachusetts, the company leverages its proprietary ActoBiotic platform to formulate topical treatments that aim to modulate the skin’s native microbial ecosystem.
The company’s lead investigational therapies are being evaluated in early-phase clinical studies for inflammatory skin disorders, including atopic dermatitis and other conditions characterized by microbial imbalance.
See Also
- Five stocks we like better than Azitra
- This $15 Stock Could Go Down as the #1 Stock of 2026
- I’m 70 With $1.5M: Would Converting $120K a Year to a Roth Be Smart or a Costly Mistake? (Ask An Advisor)
- America’s 1776 happening again
- Trump & Musk’s Secret Bet on Silver — Exposed
- Your Bank Account Is No Longer Safe
Receive News & Ratings for Azitra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azitra and related companies with MarketBeat.com's FREE daily email newsletter.
